Nil Albiol (@nilalbiol) header
Nil Albiol (@nilalbiol) profile picture

Hematologist | CAR-T cell Unit | @hospitalclinic, Barcelona | Focused in #CART/#CARTcell, #CLL, #Richter and #Lymphoma

Barcelona, Spain
Joined July 2014
Photo by Nil Albiol (@nilalbiol)Photo by Nil Albiol (@nilalbiol)Photo by Nil Albiol (@nilalbiol)Photo by Nil Albiol (@nilalbiol)Photo by Nil Albiol (@nilalbiol)Photo by Nil Albiol (@nilalbiol)Photo by Nil Albiol (@nilalbiol)Photo by Nil Albiol (@nilalbiol)Photo by Nil Albiol (@nilalbiol)Photo by Nil Albiol (@nilalbiol)
🏆 Honored that our study on ARI-0001 (varnimcabtagene autoleucel) in high-risk #CLL and #RichterTransformation has been selected for an oral presentation at #ASH26 in📍New Orleans, and recognized with an ASH Abstract Achievement. @ValentinOrtizMD @JulioDelgadoHem
7
10
44
1,574
Key outcomes: FU 28.6 mo ✅ ORR 84%
✅ CR rate 66% (72% in RT)
✅ uMRD in 83% of evaluable CLL patients
✅ Median PFS 24.8 mo in CLL, and NR in RT ✅ 2-year PFS 62% overall (54% CLL, 71% RT)
✅ No relapses among RT patients achieving CR ☢️ Grade 3-4 AE: CRS 2.6%, ICANS 0%
1
1
7
221
When? 📍 ASH Annual Meeting 2026 New Orleans 🗓️ December 12, 2026
🕑 2:00 PM - 3:30 PM
🎤 Oral Abstract Session 642: Chronic Lymphocytic Leukemia: Clinical and Epidemiological: Improving Outcomes for Relapsed/Refractory CLL/SLL
📌 MCCNO 271-273 Looking forward to see u there
2
3
434
Nil Albiol retweeted
Great to see a randomised study of CAR-T (zamto-cel) v R-GemOx, transplant ineligible relapsed DLBCL. Whilst there was EFS & PFS benefit for zamto-cel, OS the same and no obvious plateau on PFS curve. Tox of zamto is modest - all grade ICANs 11%. #lymsm thelancet.com/journals/lanon…
13
51
3,786
It’s been a pleasure to share insights from our almost 10‑year #ARI0001 (var‑cel) program, tracing its development and compassionate use results, at the @tcddublin @stjamesdublin TSJCI 13th International Cancer Conference! @hematoclinicbcn
1
4
17
988
Honoured to see our phase 2 trial on Varnimcabtagene autoleucel for R/R B-ALL published in the March issue of @LancetHaem. A meaningful milestone for hospital-based innovation in cell therapy. Pleased to discuss the study with Julio Delgado in the accompanying podcast!
🩸March issue! CD19 CAR T-cells for R/R B-cell ALL; bortezomib + vorinostat for infants with ALL; venetoclax + high-dose cytarabine + mitoxantrone for R/R AML; PROs in AML. Cover: MDS vs AML diagnostic conundrum! 🎙️shorturl.at/T5uO1 Issue here: shorturl.at/52JcK
3
14
43
4,295
🚨New in Lancet Haematology: CART19-BE-02 reports the multicentre phase 2 trial of varnimcabtagene autoleucel (var-cel), a hospital-based, point-of-care CD19 CAR T for adults with R/R B-cell precursor ALL. sciencedirect.com/science/ar… 🔓Free access link: authors.elsevier.com/c/1mYpe…
3
19
2
46
4,255
This Guidelines paper recommends prioritizing CAR T-cell therapy over bispecific antibodies or ADCs for eligible relapsed/refractory myeloma patients, as prior use of certain agents may reduce CAR T-cell effectiveness.  👉bit.ly/4rn5d5K
1
2
486
CONGRESS | #ASH25 | PRESENTATION @gabriel_brisou @paoli_calmettes shares results from a comparative analysis of axi-cel vs liso-cel as 2L therapy in real-world patients with R/R LBCL in France. After PS-weighting, there was no significant difference in OS or PFS, however, axi-cel was associated with a higher incidence of ICANS, CRS, ICU transfers and NRM vs liso-cel. Follow our live feed for more updates: loom.ly/POS6cqk Intended for HCPs only. This congress coverage is independently supported by pharmaceutical companies, who are allowed no influence on the content; a full list of supporters can be found on our website. #lymphoma #lymsm #MedicalCongress
3
5
677
CONGRESS | #ASH25 | PRESENTATION Aina Oliver-Caldes shares findings from a real-world study of patients with RRMM treated with ARI0002h (cesnicabtagene autoleucel) (N = 123). ORR was 95%, MRG-neg rate was 91%. Any grade CRS was 63%; grade 3 CRS 1.6%. Grade 1-2 ICANS in 4% of patients, comparable to the pivotal clinical trial. Follow our live feed for more updates: loom.ly/Z6rsHq8 Intended for HCPs only. This congress coverage is independently supported by pharmaceutical companies, who are allowed no influence on the content. A full list of supporters can be found on our website. #mmsm #myeloma #MedicalCongress @ainitaoliver @hospitalclinic
5
2
748
📣SAVE THE DATE VII edición: "Aspectos prácticos en aplicación clínica de terapia Chimeric Antigen Receptor T-Cell (CAR-T)". 📅23-24 Oct 2025 📍Facultat de Medicina de la Universitat de Barcelona 🗣️Información e inscripciones: aulaclinic.com/cursos/1329/v……
8
1
22
1,682
Check out our poster on the results of varnimcabtagene autoleucel (ARI0001) in CLL and Richter’s transformation! Poster no. 1905 #iwCLL2025
6
9
2
62
6,814
I will also present the results of a study evaluating the use of cell-free cfDNA MRD in CLL together with my great colleague @miguel_argdtom No. 1430 #iwCLL2025
4
21
1,331
Sure it is! Apply now!
#CRTH is just the perfect place to learn how to design a credible trial, connect with talented hematologists, and benefit from the insights of experienced mentors. We even take time to address work-life balance! If you’re interested, do not hesitate: apply before it’s too late!
4
364
CONGRESS | #SOHO2025 | PRESENTATION @niravshahmd @MedicalCollege presents phase Ia results from the phase I NX-5948-301 trial of bexobrutideg (NX-5948) in patients with R/R CLL/SLL (N = 48). Bexobrutideg was well tolerated, and responses were rapid, with an ORR of 80.9%, a median time to first response of 1.87 months. Follow our live feed for more updates: loom.ly/rBZZxmc #leusm #lymsm #MedicalCongress
2
3
864